Ciprofloxacin Blocked Enterohepatic Circulation of Diclofenac and Alleviated NSAID-induced Enteropathy in Rats Partly by Inhibiting Intestinal Β-Glucuronidase Activity
Ze-yu Zhong,Bin-bin Sun,Nan Shu,Qiu-shi Xie,Xian-ge Tang,Zhao-li Ling,Fan Wang,Kai-jing Zhao,Ping Xu,Mian Zhang,Ying Li,Yang Chen,Li Liu,Lun-zhu Xia,Xiao-dong Liu
DOI: https://doi.org/10.1038/aps.2016.54
IF: 7.169
2016-01-01
Acta Pharmacologica Sinica
Abstract:Diclofenac is a non-steroidal anti-inflammatory drug (NSAID), which may cause serious intestinal adverse reactions (enteropathy). In this study we investigated whether co-administration of ciprofloxacin affected the pharmacokinetics of diclofenac and diclofenac-induced enteropathy in rats. The pharmacokinetics of diclofenac was assessed in rats after receiving diclofenac (10 mg/kg, ig, or 5 mg/kg, iv), with or without ciprofloxacin (20 mg/kg, ig) co-administered. After receiving 6 oral doses or 15 intravenous doses of diclofenac, the rats were sacrificed, and small intestine was removed to examine diclofenac-induced enteropathy. β-Glucuronidase activity in intestinal content, bovine liver and E coli was evaluated. Following oral or intravenous administration, the pharmacokinetic profile of diclofenac displayed typical enterohepatic circulation, and co-administration of ciprofloxacin abolished the enterohepatic circulation, resulted in significant reduction in the plasma content of diclofenac. In control rats, β-glucuronidase activity in small intestinal content was region-dependent: proximal intestine